Travere Therapeutic TVTX
$47.00 −$1.30 (-2.69%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $47.29 +0.62%
Open$48.09
Prev close$48.30
Day range$46.90 – $49.35
Volume1.33M
Market cap$4.51B
P/E (TTM)–
Dividend yield–
Earnings
Average move on report day±5.1%last 16 reports
Closed higher8 of 1650% of the time
Best reaction+18.6%
Worst reaction-11.8%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 2 Nov 2026 | After Market | ±9.7% | +0.30% | Within range |
| 2026/Q2 | 4 Aug 2026 | After Market | ±13.3% | +12.03% | Within range |
| 2026/Q1 | 4 May 2026 | After Market | ±6.2% | -0.24% | Within range |
| 2025/Q4 | 19 Feb 2026 | After Market | ±18.0% | +3.72% | Within range |
| 2025/Q3 | 30 Oct 2025 | After Market | ±10.3% | +18.58% | Bigger than priced |
| 2025/Q2 | 6 Aug 2025 | After Market | ±20.9% | -1.91% | Within range |
| 2025/Q1 | 1 May 2025 | After Market | ±15.2% | +1.88% | Within range |
| 2024/Q4 | 20 Feb 2025 | After Market | ±17.1% | -6.79% | Within range |
| 2024/Q3 | 31 Oct 2024 | Pre Market | ±18.5% | -1.44% | Within range |
| 2024/Q2 | 1 Aug 2024 | After Market | ±19.0% | -2.60% | Within range |
| 2024/Q1 | 6 May 2024 | After Market | ±28.9% | +3.05% | Within range |
| 2023/Q4 | 15 Feb 2024 | After Market | ±34.7% | -6.18% | Within range |
| 2023/Q3 | 7 Nov 2023 | After Market | ±23.2% | -11.84% | Within range |
| 2023/Q2 | 3 Aug 2023 | After Market | ±14.8% | -4.67% | Within range |
| 2023/Q1 | 4 May 2023 | After Market | ±17.4% | +5.20% | Within range |
| 2022/Q4 | 23 Feb 2023 | After Market | ±11.8% | +1.92% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Where the revenue comes from
Quarter 2026/Q3
By business line
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$224.56M+36.2% YoY
Operating profit$45.01M+80.5% YoY
Net profit-$52.34M-303.6% YoY
Diluted EPS-$0.55-296.4% YoY
Free cash flow-$43.66M-3,847.6% YoY
Operating cash flow$98.20M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin98.8%
Operating margin-3.1%
Net margin-18.7%
Return on equity-252.7%
Return on assets-17.5%
Return on invested capital-23.9%
Current ratio3.00
Liabilities / assets97.3%
Cash & investments$471.82M
Total debt$609.84M
Net cash (debt)-$138.03M
No comments yet — be the first to weigh in on TVTX.
Sign in to join the discussion.